Controversies and Debates in Interventional Cardiology

Introduction

The interventional cardiology community has been forced into uncomfortable self-examination over the past two decades. Major trials challenged foundational assumptions about the value of catheterization and stenting. Geographic studies revealed dramatic variation in procedure rates that correlated with cardiologist supply rather than disease prevalence. High-profile cases of unnecessary procedures drew legal scrutiny and public attention.

These controversies matter for patients because they affect the likelihood that a catheterization recommendation reflects genuine clinical need versus practice pattern habits, financial incentives, or well-intentioned but unsupported beliefs about benefit. Understanding the debates helps patients evaluate recommendations more critically and engage more meaningfully in shared decision-making.

This article examines ongoing controversies in interventional cardiology: questions about overuse, the psychology driving intervention, geographic variation, and the arguments on all sides. The goal is not to suggest that catheterization is never appropriate—it clearly saves lives in the right circumstances—but to acknowledge genuine uncertainty about when those circumstances apply. Related articles address the clinical evidence and how to navigate decisions.

Why do some critics argue that too many catheterizations are performed in the United States?

Critics point to several concerning patterns. US catheterization rates far exceed those in other developed countries with similar or better cardiovascular outcomes. Within the US, rates vary dramatically by region in ways that correlate more with cardiologist supply than disease burden. Major trials repeatedly fail to show outcome benefits from routine catheterization in stable disease.

The economic incentives favor procedures. Catheterization and stenting generate substantial revenue for hospitals and physicians. Fee-for-service payment rewards doing more rather than achieving better outcomes. These incentives may unconsciously influence clinical judgment even among well-intentioned practitioners.

Defenders counter that US patients have better access to advanced cardiac care and that higher procedure rates reflect appropriate treatment of disease. They argue that trials enrolled lower-risk populations and that real-world patients often have characteristics making intervention more beneficial than trials suggest. The debate continues without clear resolution.

What is the “oculostenotic reflex” and why is it controversial?

The oculostenotic reflex describes the tendency to stent any blockage once visualized, regardless of whether intervention is indicated. See a stenosis, fix a stenosis. The term acknowledges that finding disease creates psychological pressure to treat it, even when evidence suggests observation or medical therapy may be equally or more appropriate.

This reflexive tendency is controversial because it short-circuits rational decision-making. The appropriate question is not “can we stent this?” but “should we stent this?” The COURAGE and ISCHEMIA trials demonstrated that for stable disease, the answer is often “no” from an outcomes standpoint—but that answer is difficult to accept when looking directly at a blockage (Boden et al., 2007).

Ad hoc PCI—stenting during the same session as diagnostic catheterization—intensifies this dynamic. The patient is already on the table, sedated, with access established. Proceeding to intervention requires only a decision; deferring requires ending the procedure, recovering the patient, and scheduling a subsequent discussion. The path of least resistance favors intervention.

How often do cardiologists disagree about whether a blockage requires intervention?

Studies assessing interobserver agreement consistently show substantial disagreement. Cardiologists reviewing identical angiograms often disagree about stenosis severity, functional significance, and whether intervention is warranted. Agreement is better for clear-cut cases—complete occlusions, obviously mild disease—but intermediate lesions produce substantial disagreement.

This disagreement reflects both technical limitations of angiography and genuine clinical uncertainty. Angiography provides a two-dimensional representation of three-dimensional anatomy; different viewing angles yield different impressions. Even with identical impressions of stenosis severity, cardiologists may reasonably differ on whether intervention will help.

The implications for patients are significant. The recommendation you receive depends partly on which cardiologist reads your images and what clinical philosophy they bring to the interpretation. Seeking a second opinion on intermediate lesions is reasonable given this documented variation in expert assessment.

What evidence suggests that visual estimation of stenosis severity is unreliable?

Validation studies comparing visual estimation to quantitative measurements reveal substantial inaccuracy. Cardiologists’ visual estimates of stenosis severity correlate only moderately with quantitative coronary angiography (QCA), which itself correlates imperfectly with functional significance assessed by FFR.

The FAME trial compared FFR-guided to angiography-guided intervention, finding that visual assessment led to overtreatment of lesions that were anatomically significant but functionally insignificant (Tonino et al., 2009). Roughly 20% of lesions appearing significant on angiography were not flow-limiting by FFR. These lesions would have received unnecessary stents without physiological assessment.

The fundamental problem is that percent stenosis—a two-dimensional reduction in diameter—does not reliably predict three-dimensional flow dynamics. Eccentric plaque, lesion length, serial stenoses, and the territory supplied all influence whether a given stenosis actually impairs perfusion. Visual estimation captures only one dimension of this complex picture.

Why has the use of FFR remained lower than guidelines recommend?

Despite strong evidence supporting FFR-guided decision-making, utilization remains below what guidelines recommend. Surveys suggest FFR is used in only 10-30% of procedures where it might inform decision-making. This gap between evidence and practice raises questions about implementation barriers.

Several factors limit FFR adoption. The measurement adds procedure time—typically 5-10 minutes per lesion. Equipment costs include pressure wires and adenosine for hyperemia induction. Some patients experience side effects from adenosine including chest discomfort and transient shortness of breath. Operators comfortable with visual assessment may feel FFR is unnecessary.

Economic incentives may paradoxically discourage FFR use. FFR measurement is reimbursed, but it often results in deferring intervention—which is not reimbursed. An operator who measures FFR and finds a lesion non-significant has done work but foregone the revenue from stent placement. The incentive structure favors skipping FFR and treating based on angiography alone.

---

Discover the tests and treatments that could save your life

Get our unbiased and comprehensive report on the latest techniques for heart disease prevention, diagnosis, and treatment.

---

What is the controversy around “ad hoc” PCI?

Ad hoc PCI refers to performing intervention during the same procedure session as diagnostic catheterization, without a separate discussion period. The practice is common—roughly 60-70% of PCI in the US occurs ad hoc. Proponents argue it avoids a second procedure with its associated access, contrast, and recovery. Critics argue it pressures patients into immediate intervention decisions.

The controversy centers on informed consent and shared decision-making. A patient who agreed to diagnostic catheterization may not have anticipated same-session intervention. The sedation, time pressure, and vulnerability of the procedure setting compromise thoughtful deliberation. Patients report feeling they had little choice once blockages were found.

The ORBITA trial’s sham-controlled design required separating diagnosis from treatment—all patients had diagnostic catheterization first, then returned later for randomization (Al-Lamee et al., 2018). This design revealed the placebo effect of PCI that ad hoc approaches cannot detect. It also demonstrated that delaying intervention for deliberation does not compromise outcomes.

How accurate is catheterization at identifying which blockages will cause future heart attacks?

Poorly. The assumption that severe blockages cause heart attacks is intuitively appealing but empirically questionable. Studies tracking which lesions cause future events consistently find that heart attacks often arise from lesions that appeared modest at prior catheterization.

The biology explains this paradox. Heart attacks typically result from plaque rupture and thrombosis, not gradual progression of stenosis. Vulnerable plaques prone to rupture are characterized by large lipid cores, thin fibrous caps, and inflammation—features invisible on angiography. A 40% stenosis made of vulnerable plaque may pose greater near-term danger than a stable 80% calcified lesion.

This limitation undermines the logic of prophylactic intervention for stable disease. Stenting the most severe-appearing lesion does not prevent events from other vulnerable plaques throughout the coronary tree (Calvert et al., 2011). Medical therapy addressing systemic atherosclerosis may prevent events that focal intervention cannot.

Why do many heart attacks occur in arteries without severe blockages?

Autopsy studies and serial imaging studies consistently show that many infarctions arise from lesions that were not severely stenotic before the event. The culprit lesion that caused a STEMI may have appeared as a 30-50% stenosis on prior imaging. This paradox challenges the model of progressive stenosis leading to occlusion.

The mechanism involves plaque vulnerability rather than stenosis severity. Thin-cap fibroatheromas with large lipid-rich necrotic cores are prone to rupture even at modest sizes. When the cap ruptures, exposure of thrombogenic material to flowing blood triggers acute thrombosis that can completely occlude the artery within minutes.

This biology has profound implications for prevention strategy. Finding and fixing severe stenoses does not address the greater threat from less-severe vulnerable plaques. Systemic therapies—aggressive lipid lowering, anti-inflammatory treatment, antiplatelet agents—address plaque biology throughout the coronary tree in ways that focal stenting cannot.

What are the arguments for and against more conservative approaches to catheterization?

Conservative approach advocates cite trial evidence showing no mortality benefit from routine catheterization in stable disease, procedural risks that provide no offsetting benefit, opportunity costs of unnecessary procedures, and psychological harms of finding disease that would be better left undiscovered.

They emphasize that medical therapy has improved dramatically. Contemporary risk factor management—high-intensity statins, blood pressure control, diabetes management—may be more important than mechanical revascularization for long-term outcomes. Aggressive lifestyle intervention can achieve plaque regression that intervention cannot.

Intervention advocates counter that trials enrolled selected populations and may not generalize. They argue that some patients clearly benefit from revascularization—particularly those with refractory symptoms—and that denying catheterization to these patients harms them. They note that progression of conservatively managed disease can lead to MI or death, outcomes that timely intervention might have prevented.

How does geographic variation in catheterization rates raise questions about appropriateness?

The Dartmouth Atlas and similar projects document dramatic variation in cardiac procedure rates across regions. Some areas perform two to three times as many catheterizations per capita as others. This variation exceeds any plausible difference in disease prevalence.

The variation correlates with supply factors more than demand factors. Regions with more cardiologists, more cath labs, and more hospital beds perform more procedures. The relationship suggests that the availability of services drives their use, independent of clinical need—a phenomenon economists call supplier-induced demand.

Outcomes do not clearly favor high-procedure regions. If more catheterization produced better outcomes, high-rate regions should have lower cardiovascular mortality. They generally do not. This observation challenges the assumption that more intervention equals better care and raises questions about how much catheterization is truly necessary.

What scandals or high-profile cases have involved unnecessary cardiac catheterizations?

Several cases have drawn legal and media attention. In 2013, a cardiologist in Kentucky was convicted of performing unnecessary procedures including catheterizations on patients without significant disease. Similar cases have occurred at other institutions where patterns of inappropriate intervention were identified.

These dramatic cases represent extreme examples of a more widespread phenomenon. Audits comparing catheterization decisions to appropriate use criteria consistently find that 10-20% or more of procedures fail to meet appropriateness standards. Most inappropriate procedures are not the result of fraud but of judgment that differs from evidence-based guidelines.

The existence of such cases underscores the importance of patient awareness and engagement. Assuming every recommended procedure is necessary—without understanding the evidence, asking questions, or seeking second opinions—may not serve patients’ interests when financial incentives and practice culture can influence recommendations.

---

Discover the tests and treatments that could save your life

Get our unbiased and comprehensive report on the latest techniques for heart disease prevention, diagnosis, and treatment.

---

Why might financial incentives lead to overuse of catheterization?

Catheterization and stenting generate substantial revenue. Hospitals invest millions in catheterization laboratories and need sufficient volume to maintain them. Interventional cardiologists whose compensation depends on procedure volume have financial interest in performing more procedures.

Fee-for-service payment exacerbates this dynamic. Doing more generates more income. A cardiologist who measures FFR, finds a lesion non-significant, and defers intervention earns less than one who stents the lesion without measuring FFR. The economic incentive opposes the evidence-based approach.

These incentives do not make practitioners malicious. Most cardiologists believe they are helping patients. But financial incentives can unconsciously influence judgment, causing practitioners to weight ambiguous evidence toward intervention. The structural solution requires payment reform that rewards outcomes over volume, an ongoing challenge in healthcare policy.

What do critics mean when they say interventional cardiology treats the “wrong” lesions?

Critics argue that intervention targets the most severe-appearing stenoses while heart attacks arise from less-severe vulnerable plaques. Stenting a stable 80% blockage does not prevent an event from a different 40% lesion that ruptures. The intervention addresses visible anatomy rather than the biology that actually causes events.

This critique does not argue that stenting never helps. For acute MI, opening the culprit occlusion saves lives. For refractory angina, revascularization can relieve symptoms. The critique targets prophylactic intervention for asymptomatic or mildly symptomatic stable disease, where the rationale depends on preventing events—a goal intervention may not achieve.

The alternative approach emphasizes systemic therapy over focal intervention. Lowering LDL cholesterol, reducing inflammation, preventing thrombosis—these strategies address disease biology throughout the arterial tree. Lifestyle modification can achieve benefits that intervention cannot. From this perspective, the focus on finding and fixing blockages distracts from more effective prevention.

How do catheterization rates in the US compare to other developed countries?

US catheterization rates substantially exceed those in most other developed countries. The US performs roughly twice as many catheterizations per capita as the UK and considerably more than most European countries. Similar disparities exist for PCI and CABG.

This gap is not explained by worse cardiovascular outcomes in other countries. Many countries with lower intervention rates achieve similar or better cardiovascular mortality. The US ranks poorly among developed nations on life expectancy and cardiovascular outcomes despite leading in procedure rates.

Explanations for the difference include payment systems (fee-for-service vs. global budgets), medicolegal environment (defensive practice), cultural expectations (patient and physician), and supply factors (more cath labs and cardiologists per capita). The comparison challenges assumptions that more intervention produces better outcomes.

What is the debate about catheterization in elderly patients with limited life expectancy?

Older patients face heightened procedural risks from catheterization while having less potential lifetime benefit from any treatment. A stent that prevents an event ten years in the future provides no benefit to someone with five-year life expectancy. Frailty, cognitive impairment, and competing causes of death all affect the risk-benefit calculation.

Conservative physicians argue that aggressive intervention in elderly patients often provides little benefit while imposing significant burdens—hospitalization, procedural risks, recovery time, medication complexity. The goal of care should emphasize quality of life and avoiding harm, which may mean accepting some coronary disease without pursuing invasive characterization or treatment.

Interventionists counter that age alone should not determine treatment. Some 85-year-olds are robust with long remaining life expectancy; some 65-year-olds are frail. Symptomatic coronary disease impairs quality of life regardless of age. Denying effective treatment based on age alone is discriminatory.

The resolution lies in individualized assessment considering life expectancy, functional status, goals of care, and patient preferences rather than applying uniform policies based on age. But this requires honest conversations about prognosis that can be uncomfortable for patients and physicians alike.

Conclusion

Controversies surrounding cardiac catheterization reflect genuine uncertainty about when the procedure benefits patients. The evidence does not support routine catheterization for stable disease. Geographic variation and financial incentives raise questions about appropriate use. The oculostenotic reflex and ad hoc PCI practices may drive intervention beyond what evidence supports.

These debates do not mean catheterization is never appropriate—it clearly saves lives in acute myocardial infarction and provides symptomatic relief for some patients. But they suggest patients should not accept catheterization recommendations uncritically. Understanding the controversies enables more informed engagement with your cardiologist about whether catheterization is truly indicated for your specific situation.

The next articles address physician incentives and practice variation and how to navigate catheterization decisions when faced with recommendations in this uncertain landscape.